RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000020.xml
![](/products/assets/desktop/img/oa-logo.png)
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(12): 1273-1277
DOI: 10.1055/a-1019-7720
DOI: 10.1055/a-1019-7720
GebFra Science
Statement/Stellungnahme
Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019
Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO) Artikel in mehreren Sprachen: English | deutschWeitere Informationen
Publikationsverlauf
received 25. September 2019
accepted 26. September 2019
Publikationsdatum:
11. Dezember 2019 (online)
![](https://www.thieme-connect.de/media/gebfra/201912/lookinside/thumbnails/10-1055-a-1019-7720_gf_en-1.jpg)
Abstract
The role of adjuvant radiotherapy and/or chemotherapy in the primary treatment of endometrial cancer with a high risk of recurrence has still not been conclusively determined. The results of 3 large randomized controlled studies on different aspects of this issue have been published in full in recent months, and the relevant results are analyzed here.
-
References/Literatur
- 1 de Boer SM, Powell ME, Mileshkin L. et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19: 295-309 doi:10.1016/S1470-2045(18)30079-2
- 2 Deutsche Gesellschaft für Radioonkologie (DEGRO). Hoch-Risiko-Endometriumkarzinom: Adjuvante Strahlentherapie bleibt Therapiestandard. Online: https://www.degro.org/hoch-risiko-endometriumkarzinom-adjuvante-strahlentherapie-bleibt-therapiestandard/ last access: 02.08.2019
- 3 Kommission Uterus der Arbeitsgemeinschaft Onkologie (AGO). S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom. Version 1.0 – April 2018 AWMF-Registernummer: 032/034-OL. Online: https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/ last access: 30.05.2018
- 4 Emons G, Tempfer C, Battista MJ. et al. Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study. Geburtsh Frauenheilk 2018; 78: 923-926 doi:10.1055/a-0658-1918
- 5 de Boer SM, Powell ME, Mileshkin L. et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; DOI: 10.1016/S1470-2045(19)30395-X.
- 6 Matei D, Filiaci V, Randall ME. et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 2019; 380: 2317-2326 doi:10.1056/NEJMoa1813181
- 7 Randall ME, Filiaci V, McMeekin DS. et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol 2019; 37: 1810-1818 doi:10.1200/JCO.18.01575
- 8 Ho JC, Allen PK, Jhingran A. et al. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol 2015; 139: 40-46 doi:10.1016/j.ygyno.2015.07.096
- 9 Emons G, Vordermark D. Adjuvant treatment for endometrial cancer. Curr Opin Oncol 2019; 31: 404-410 doi:10.1097/CCO.0000000000000558